0001493152-24-010998.txt : 20240322 0001493152-24-010998.hdr.sgml : 20240322 20240322163933 ACCESSION NUMBER: 0001493152-24-010998 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20240319 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240322 DATE AS OF CHANGE: 20240322 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NUTRA PHARMA CORP CENTRAL INDEX KEY: 0001119643 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 912021600 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-32141 FILM NUMBER: 24775829 BUSINESS ADDRESS: STREET 1: 12538 W. ATLANTIC BLVD. CITY: CORAL SPRINGS STATE: FL ZIP: 33071 BUSINESS PHONE: (954) 509-0911 MAIL ADDRESS: STREET 1: 12538 W. ATLANTIC BLVD. CITY: CORAL SPRINGS STATE: FL ZIP: 33071 FORMER COMPANY: FORMER CONFORMED NAME: CYBER VITAMIN COM DATE OF NAME CHANGE: 20000717 8-K 1 form8-k.htm
false 0001119643 0001119643 2024-03-19 2024-03-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of

The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): March 19, 2024

 

NUTRA PHARMA CORP.

(Exact name of registrant as specified in its charter)

 

California   000-32141   91-2021600
(State or other jurisdiction
of incorporation)		   (Commission
File Number)		   (I.R.S. Employer
Identification No.)

 

6400 Park of Commerce Blvd.
Suite 1B

Boca Raton, Florida 33487

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: 954-509-0911

 

1537 NW 65th Avenue
Plantation, FL 33313

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered under Section 12(b) of the Exchange Act:

 

Title of class   Trading symbol   Name of each exchange on which registered
N/A   N/A   N/A

 

 

 

 

 

 

Nutra Pharma Corp. is referred to herein as “we,” “our,” “us,” or the “Company”.

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

Resignation of Rik J. Deitsch as our Chief Executive Officer, Director, Chairman of the Board, and Chief Financial Officer

 

As a result of the Company’s and Mr. Deitsch’s respective settlements with the Securities and Exchange Commission (the “SEC” or “Commission”) as further discussed below under Item 8.01, on March 19, 2024, Mr. Deitsch submitted a letter of resignation to our Board of Directors and thereby resigned as Chief Executive Officer, Director, Chairman of the Board, and Chief Financial Officer of Nutra Pharma Corp., effective immediately. Following his resignation as an officer and director of the Company, Mr. Deitsch will continue to work for the Company in a new role as the Company’s Operations Manager. Mr. Deitsch was appointed as the Company’s Operations Manager by our Board of Directors effective March 19, 2024.

 

Appointment of Dr. Michael Flax as our Chairman, Chief Financial Officer and Chief Executive Officer

 

On March 20, 2024, our Board of Directors unanimously approved of the appointment of Michael Flax, DDS as our Chief Executive Officer, Director, Chairman of the Board and Chief Financial Officer. Dr. Flax served previously as the Company’s President and Chief Executive Officer and as a member of our Board of Directors.

 

Dr. Michael Flax’s Biographical Information

 

Michael D. Flax, D.D.S., M.S., P.A. (69) was previously President and Chief Executive Officer of Nutra Pharma Corp. from November 2001 through November 2002. He also served as a Director of Nutra Pharma Corp. from November 2001 through June 2005.

 

From 2020 through the present, Dr. Flax has served on the Board of Appeals for United Healthcare of Fort Lauderdale, Florida. From July of 2011 through August of 2020, he served as the Program Director for Graduate Endodontics for the Nova Southeastern College of Dental Medicine in Fort Lauderdale. From May of 1998 through August of 2020, Dr. Flax served as the CEO and Co-Founder of Solstice Benefits in Fort Lauderdale. From August of 1996 through August of 2011, he served as an Associate Professor of Endodontics for the Nova Southeastern College of Dental Medicine in Fort Lauderdale. From June of 1986 through June of 2011, he was self-employed in the practice of Endodontics in Coral Springs, Florida. From 1986 through 1991, Dr. Flax served as an Instructor for the Department of Endodontics at the University of Pennsylvania School of Medicine – Graduate Division in Philadelphia, Pennsylvania. From 1986 through 1991, Dr. Flax served as an Instructor for the Department of Endodontics at Temple University School of Dentistry in Philadelphia, Pennsylvania. Dr. Flax is a Diplomate of the American Board of Endodontics, a member of the American Association of Endodontics, and a Fellow of the American College of Dentists.

 

Dr. Flax has several research papers and presentations including work on the solubility and biocompatibility of calcium hydroxide-containing root canal sealer as well as investigations into anaerobic bacteria in periapical lesions of human teeth. He also worked in medical devices and developed adhesives for pipettes during autoclave procedures.

 

Dr. Michael Flax holds a certificate from the University of Pennsylvania School of Dental Medicine in Endodontics, 1986, a D.D.S. from Georgetown University Dental School, 1981, an M.S. in chemistry from St. John’s University, 1977, and a B.A. major in chemistry, minor in engineering from Miami University in Oxford, Ohio. He is licensed to practice dentistry in the states of Florida, Maryland, New York, Pennsylvania, and the District of Columbia.

 

Item 7.01 Regulation FD Disclosure.

 

On March 22, 2024, the Company issued a press release regarding the bifurcated settlements with the Commission in Item 8.01 of this Current Report on Form 8-K; a copy of such press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated in this Item 7.01 by reference. The information included in this Item 7.01 and in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

 

 

 

Item 8.01 Other Events.

 

On March 19, 2024, the U.S. District Court for the Eastern District of New York (the “Court”) in SEC v. Nutra Pharma Corporation, Erik Deitsch a/k/a Rik Deitsch, and Sean Peter McManus, Case No. 1:18-cv-05459-JS (E.D.N.Y.), approved bifurcated settlements in the form of partial consent judgments (the “Consent Judgments”) entered by the Court. Pursuant to the Consent Judgments, the Company, Rik Deitsch and Sean McManus (collectively, the “Defendants”), without admitting or denying the allegations of the Complaint except as to jurisdiction and solely in respect of Mr. Deitsch and Mr. McManus, except as to certain exceptions to discharge under Section 523 of the Bankruptcy Code, resolved all liability issues as to each Defendant and certain remedies as to Mr. Deitsch and left open other issues relating to remedies regarding the appropriateness and amount of disgorgement and/or civil penalties to be paid as to all Defendants, and whether a penny stock bar shall be imposed against Mr. McManus, and if so, the length of any such bar, for later resolution by the Court upon motion or further settlement. The Consent Judgments, among other things:

 

  (1) Permanently enjoin Nutra Pharma Corp. from committing violations of the federal securities laws that the SEC has alleged in the case, including violations of Sections 5(a), 5(c), and 17(a) of the Securities Act, Sections 10(b) and 13(a) of the Securities Exchange Act, and Rules 10b-5, 13a-11, and 13a-13 thereunder;
     
  (2) Permanently enjoin Rik Deitsch from committing violations of the federal securities laws that the SEC has alleged in this case, including violations of Sections 5(a), 5(c), and 17(a) of the Securities Act, Sections 9(a)(2), 10(b), 13(a), 13(d), and 16(d) of the Securities Exchange Act, and Rules 10b-5, 13a-14, 13d-2, and 16a-3 thereunder; impose a three-year officer-and-director bar on Deitsch, pursuant to 15 U.S.C. §§ 77t(e) and 78u(d)(2); and impose a three-year penny-stock bar on Deitsch, pursuant to 15 U.S.C. § 78u(d)(6); and
     
  (3) Permanently enjoin Sean McManus from committing violations of the federal securities laws that the SEC has alleged in the case, including violations of Section 17(a) of the Securities Act and Sections 10(b) and 15(a) of the Exchange Act and Rule 10b-5 thereunder.

 

As described above, the Consent Judgments leave open for later resolution by the Court upon motion or further settlement the amounts of disgorgement, if any, and/or civil penalties, if any, to be paid as to all Defendants, and whether a penny stock bar shall be imposed as to Sean McManus, and if so, the length of any such bar.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

99.1   Press Release of the Company dated March 22, 2024.
99.2   Resignation Letter of Rik J. Deitsch
104   Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)

 

 

 

 

INDEX OF EXHIBITS

 

Exhibit No.   Description
99.1   Press Release of the Company dated March 22, 2024
99.2   Resignation Letter of Rik J. Deitsch
104   Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  NUTRA PHARMA CORP.
   
Dated: March 22, 2024 By: /s/ Michael Flax, DDS
    Michael Flax
    Chief Executive Officer, Chief Financial Officer and Chairman of the Board

 

 

 

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

 

Contact:

Nutra Pharma Corp.

Nina Goldstein

877-895-5647

IR@nutrapharma.com

 

Nutra Pharma Corp. Reaches Settlement with SEC

 

Nutra Pharma Corp. has reached a bifurcated settlement with the SEC along with its CEO and a Consultant to the company.

 

March 22, 2024 -- Coral Springs, Florida -- Nutra Pharma Corporation (OTC: NPHC), (“Nutra Pharma” or the “Company”) reached a settlement with the U.S. Securities and Exchange Commission (“SEC”) earlier this week.

 

On March 19, 2024, the United States District Court for the Eastern District of New York in SEC v. Nutra Pharma Corporation, Erik Deitsch a/k/a Rik Deitsch, and Sean Peter McManus, Case No. 1:18-cv-05459-JS (E.D.N.Y.), approved bifurcated settlements in the form of consent judgments (the “Consent Judgments”) entered by the Court, wherein the Defendants, without admitting or denying the allegations of the Complaint except as to personal and subject matter jurisdiction, resolved all liability issues and certain remedies as to each Defendant and left open other issues relating to remedies regarding the appropriateness and amount of disgorgement and/or civil penalties to be paid as to all Defendants, and whether a penny stock bar shall be imposed against Defendant McManus, and if so, the length of any such bar, for later resolution by the Court upon motion or further settlement. The Consent Judgments, among other things:

 

(1) Permanently enjoin Defendant Nutra Pharma from committing violations of the federal securities laws that the SEC has alleged in this case, including violations of Sections 5(a), 5(c), and 17(a) of the Securities Act of 1933 (the “Securities Act”), Sections 10(b) and 13(a) of the Securities Exchange Act of 1934 (the “Exchange Act”), and Rules 10b-5, 13a-11, and 13a-13 thereunder;

 

(2) Permanently enjoin Defendant Deitsch from committing violations of the federal securities laws that the SEC has alleged in this case, including violations of Sections 5(a), 5(c), and 17(a) of the Securities Act, Sections 9(a)(2), 10(b), 13(a), 13(d), and 16(d) of the Securities Exchange Act, and Rules 10b-5, 13a-14, 13d-2, and 16a-3 thereunder; impose a three-year officer-and-director bar on Deitsch, pursuant to 15 U.S.C. §§ 77t(e) and 78u(d)(2); and impose a three-year penny-stock bar on Deitsch, pursuant to 15 U.S.C. § 78u(d)(6); and

 

(3) Permanently enjoin Defendant McManus from committing violations of the federal securities laws that the SEC has alleged in this case, including violations of Section 17(a) of the Securities Act and Sections 10(b) and 15(a) of the Exchange Act and Rule 10b-5 thereunder.

 

“Pursuant to our settlement with the SEC, I have tendered my resignation as Chairman and CEO of Nutra Pharma Corp effective March 19th,” stated Rik J Deitsch. “The Company’s former CEO, Dr. Michael Flax, will resume this position effective immediately and also serve as Nutra Pharma’s Chairman and CFO,” he continued. “This is an exciting time for the Company as we have an opportunity to move our operations ahead and fulfill on the promises of our portfolio of products and our Intellectual Property,” he concluded.

 

   
 

 

Following his resignation as an officer and director of the Company, our Board of Directors has appointed Mr. Deitsch to the position of Operations Manager: reporting to Joe Lucas, VP of Operations.

 

“It’s great to be back at Nutra Pharma,” commented Michael Flax, DDS; incoming Chairman and CEO of Nutra Pharma Corp. “I’ve been a former officer and long-term investor in the Company and I’m excited to be part of its future,” he continued. “We have a lot of things planned as we get past the issues the Company has been facing over the last five years and move into our next phase of growth, including: planned retail rollouts, clinical trials on our ethical drugs and expansion of contract manufacturing at our new facility in Boca Raton,” he concluded.

 

The Company expects to have updates shortly as the new Executive team executes on their business plan.

 

About Nutra Pharma Corp.

 

Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. Additionally, the Company markets drug products for sale for the treatment of pain under the brand Nyloxin® and Pet Pain-Away™. For additional information about Nutra Pharma, visit:

http://www.NutraPharma.com or

http://www.nyloxin.com

http://www.petpainaway.com

 

SEC Disclaimer

 

This press release contains forward-looking statements. The words or phrases “would be,” “will allow,” “intends to,” “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimate,” “project,” or similar expressions are intended to identify “forward-looking statements.” Actual results could differ materially from those projected in Nutra Pharma’s (“the Company”) business plan. The Company’s filings may be accessed at the SEC’s Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

 

# # #

 

   

 

 EX-99.2 3 ex99-2.htm

 

Exhibit 99.2

 

RIK J DEITSCH

6400 Park of Commerce Blvd ♦ Suite 1B

Boca Raton, FL 33487

Office (954) 509-0911 ♦ Fax (866) 744-3655

 

March 19, 2024

 

Board of Directors

Nutra Pharma Corporation

 

Members of the Board:

 

Pursuant to my settlement with the Securities and Exchange Commission (SEC) I am resigning as Chief Executive Officer, Director, Chairman of the Board, and Chief Financial Officer of Nutra Pharma Corporation effective immediately.

 

Sincerely,  
 
Rik J Deitsch  

 

 

 

 GRAPHIC 4 ex99-1_001.jpg begin 644 ex99-1_001.jpg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ex99-2_001.jpg begin 644 ex99-2_001.jpg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end EX-101.SCH 6 nphc-20240319.xsd INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 7 nphc-20240319_lab.xml INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 8 nphc-20240319_pre.xml INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 10 R1.htm IDEA: XBRL DOCUMENT v3.24.1
Cover
Mar. 19, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 19, 2024
Entity File Number 000-32141
Entity Registrant Name NUTRA PHARMA CORP.
Entity Central Index Key 0001119643
Entity Tax Identification Number 91-2021600
Entity Incorporation, State or Country Code CA
Entity Address, Address Line One 6400 Park of Commerce Blvd.
Entity Address, Address Line Two Suite 1B
Entity Address, City or Town Boca Raton
Entity Address, State or Province FL
Entity Address, Postal Zip Code 33487
City Area Code 954
Local Phone Number 509-0911
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 15 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1 html 1 19 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://nutrapharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports [dq-60540-EntityEmergingGrowthCompany-Missing] Submission type 8-K should have a non-empty value for EntityEmergingGrowthCompany in the Required Context. form8-k.htm form8-k.htm nphc-20240319.xsd nphc-20240319_lab.xml nphc-20240319_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 18 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form8-k.htm": { "nsprefix": "NPHC", "nsuri": "http://nutrapharma.com/20240319", "dts": { "inline": { "local": [ "form8-k.htm" ] }, "schema": { "local": [ "nphc-20240319.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "nphc-20240319_lab.xml" ] }, "presentationLink": { "local": [ "nphc-20240319_pre.xml" ] } }, "keyStandard": 19, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 19 }, "report": { "R1": { "role": "http://nutrapharma.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-03-19", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-19", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://nutrapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://nutrapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://nutrapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://nutrapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://nutrapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://nutrapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://nutrapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://nutrapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://nutrapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://nutrapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://nutrapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://nutrapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://nutrapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://nutrapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://nutrapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://nutrapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://nutrapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://nutrapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://nutrapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://nutrapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://nutrapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://nutrapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://nutrapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://nutrapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://nutrapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://nutrapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://nutrapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://nutrapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://nutrapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://nutrapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://nutrapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://nutrapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://nutrapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://nutrapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://nutrapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://nutrapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://nutrapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://nutrapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://nutrapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://nutrapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://nutrapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://nutrapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://nutrapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://nutrapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://nutrapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://nutrapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://nutrapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://nutrapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://nutrapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://nutrapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://nutrapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://nutrapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://nutrapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://nutrapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://nutrapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://nutrapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://nutrapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://nutrapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 19 0001493152-24-010998-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-24-010998-xbrl.zip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end XML 21 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001119643 2024-03-19 2024-03-19 iso4217:USD shares iso4217:USD shares false 0001119643 8-K 2024-03-19 NUTRA PHARMA CORP. CA 000-32141 91-2021600 6400 Park of Commerce Blvd. Suite 1B Boca Raton FL 33487 954 509-0911 false false false false